Home » Stocks » Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc. (APLS)

Stock Price: $34.05 USD 0.29 (0.86%)
Updated Oct 20, 2020 9:32 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 2.57B
Revenue (ttm) n/a
Net Income (ttm) -470.48M
Shares Out 75.60M
EPS (ttm) -6.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $34.05
Previous Close $33.76
Change ($) 0.29
Change (%) 0.86%
Day's Open -
Day's Range 33.95 - 34.20
Day's Volume 2,816
52-Week Range 16.85 - 45.04

More Stats

Market Cap 2.57B
Enterprise Value 2.10B
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 75.60M
Float 58.98M
EPS (basic) -7.07
EPS (diluted) -6.79
FCF / Share -4.50
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10.90M
Short Ratio 17.50
Short % of Float 18.47%
Beta 1.15
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 11.52
Revenue n/a
Operating Income -390.31M
Net Income -470.48M
Free Cash Flow -339.91M
Net Cash 471.83M
Net Cash / Share 6.24
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -41.10%
ROE -240.56%
ROIC -121.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (14)

Buy 10
Overweight 1
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(51.60% upside)
Current: $34.05
Target: 51.62
*Average 12-month price target from 13 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-288-128-50.91-27.26-46.57
Net Income-305-128-51.01-27.12-46.52
Shares Outstanding62.2354.4013.878.435.80
Earnings Per Share-4.90-2.34-3.68-3.22-8.03
Operating Cash Flow-211-131-46.60-26.00-18.86
Capital Expenditures-1.69----
Free Cash Flow-213-131-46.60-26.00-18.86
Cash & Equivalents35217617624.8636.00
Total Debt15727.0426.39--
Net Cash / Debt19514914924.8636.00
Book Value34.2316114923.7934.98
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Apellis Pharmaceuticals, Inc.
Country United States
Employees 297
CEO Cedric Francois

Stock Information

Ticker Symbol APLS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: APLS
IPO Date November 9, 2017


Apellis Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Waltham, Massachusetts.